Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis

Sikora, Mariusz; Stec, Albert; Chrabąszcz, Magdalena; Waśkiel‐Burnat, Anna; Zaremba, Michał; Olszewska, Małgorzata; Rudnicka, Lidia

doi:10.3390/jcm8071021

Cited by 51 publications

(43 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that psoriasis patients had more elevated concentration of plasma claudin-3 and I-FABP, supporting the hypothesis that dysfunction of the intestinal barrier in psoriasis disturbs the homeostatic equilibrium between the microbiota and immune system. In another study conducted by Sikora confirmed that I-FABP is associated with severity of psoriasis ( Sikora et al, 2019 ). The putative relationship between gut dysbiosis and psoriasis development and progression have been shown in Figure 1 .…”

Section: Gut Microbiome and Psoriasismentioning

confidence: 86%

“…Ethanol extract (SEL001), isolated from the potent probiotic strain Lactobacillus sakei proBio-65, has a protective effect on imiquimod-treated psoriasis-like skin inflammation in a mouse model, with decreased gene expression levels of IL-19, IL-17A, and IL-23 ( Rather et al, 2018 ). In a documented case of severe pustular psoriasis that did not respond to steroids, dapathon, and methotrexate, clinical improvement was observed within 2 weeks after initiation of Lactobacillus sporogenes supplementation three times a day, and almost complete resolution was observed at 4 weeks ( Sikora et al, 2019 ). In a separate placebo-controlled study of psoriasis patients, Bifidobacterium infantis 35624 supplementation resulted in significantly reduced plasma levels of TNF-α, IL-6 and C-reactive protein (CRP) in the probiotic-treated group ( Groeger et al, 2013 ).…”

Section: Modulation Of the Gut Microbiota For Prevention And Treatmenmentioning

confidence: 99%

See 1 more Smart Citation

Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies

Chen

Zhu

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

Psoriasis affects the health of myriad populations around the world. The pathogenesis is multifactorial, and the exact driving factor remains unclear. This condition arises from the interaction between hyperproliferative keratinocytes and infiltrating immune cells, with poor prognosis and high recurrence. Better clinical treatments remain to be explored. There is much evidence that alterations in the skin and intestinal microbiome play an important role in the pathogenesis of psoriasis, and restoration of the microbiome is a promising preventive and therapeutic strategy for psoriasis. Herein, we have reviewed recent studies on the psoriasis-related microbiome in an attempt to confidently identify the “core” microbiome of psoriasis patients, understand the role of microbiome in the pathogenesis of psoriasis, and explore new therapeutic strategies for psoriasis through microbial intervention.

show abstract

Section: Gut Microbiome and Psoriasismentioning

confidence: 86%

Section: Modulation Of the Gut Microbiota For Prevention And Treatmenmentioning

confidence: 99%

Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies

Chen

Zhu

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…In complex interactions in the gut-skin axis, psoriasis severity should also be considered in addition to the microbiome and intestinal barrier. It has been shown that Psoriasis Activity and Severity Index (PASI) positively correlates with the blood concentration of intestinal barrier damage biomarkers [46,47]. Much less is known about the potential relationship between the composition of gut microbiome and the severity of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiome in Psoriasis: An Updated Review

et al. 2020

Self Cite

View full text Add to dashboard Cite

(1) Background: A growing body of evidence highlights that intestinal dysbiosis is associated with the development of psoriasis. The gut–skin axis is the novel concept of the interaction between skin diseases and microbiome through inflammatory mediators, metabolites and the intestinal barrier. The objective of this study was to synthesize current data on the gut microbial composition in psoriasis. (2) Methods: We conducted a systematic review of studies investigating intestinal microbiome in psoriasis, using the PRISMA checklist. We searched MEDLINE, EMBASE, and Web of Science databases for relevant published articles (2000–2020). (3) Results: All of the 10 retrieved studies reported alterations in the gut microbiome in patients with psoriasis. Eight studies assessed alpha- and beta-diversity. Four of them reported a lack of change in alpha-diversity, but all confirmed significant changes in beta-diversity. At the phylum-level, at least two or more studies reported a lower relative abundance of Bacteroidetes, and higher Firmicutes in psoriasis patients versus healthy controls. (4) Conclusions: There is a significant association between alterations in gut microbial composition and psoriasis; however, there is high heterogeneity between studies. More unified methodological standards in large-scale studies are needed to understand microbiota’s contribution to psoriasis pathogenesis and its modulation as a potential therapeutic strategy.

show abstract

“…Recent reviews also list potential biomarkers that could be detected in excreta [7]. Intestinal fatty acid binding proteins is cytoplasmic protein exclusive to the intestinal enterocytes and can be regarded as a biomarker [8]. Other potential biomarkers include lipocalin 2 [9], ovotransferrin [10], superoxide dismutase [11], fibronectin [4] and intestinal alkaline phosphatase [12].…”

Section: Introductionmentioning

confidence: 99%

Excreta biomarkers in response to different gut barrier dysfunction models and probiotic supplementation in broiler chickens

et al. 2020

View full text Add to dashboard Cite

Increased intestinal permeability (IP) and inflammation are both linked with functionality of the intestinal barrier and in particular enterocytes. Currently, almost all assessment methods of the intestinal barrier function are invasive. The present study aimed to quantify selected proteins as novel biomarkers in excreta of broiler chickens to facilitate non-invasive assessment of gut barrier function using enzyme-linked immunosorbent assays (ELISA). It was further hypothesised that probiotics as feed additives may counteract gut barrier dysfunction. A 3 × 2 factorial arrangement of treatments was used with the main factors being gut barrier dysfunction models (control, rye-based diet, and dexamethasone-DEX) with and without probiotic supplementation (a three-strain Bacillus) using 72 male Ross 308 day-old chickens. Each of the 6 experimental treatments was replicated 12 times. On d 21 of age, fluorescein isothiocyanate dextran (FITC-d) uptake into serum was examined to test IP. Fresh excreta samples were collected on d 20. The biomarkers included alpha-1 antitrypsin (A1AT), intestinal fatty acid binding protein (I-FABP), lipocalin-2 (LCN2), fibronectin (FN), intestinal alkaline phosphatase (IAP), ovotransferrin (OVT) and superoxide dismutase [Cu-Zn] (SOD1). Only DEX increased (P<0.001) FITC-d passage to the blood on d 21 of age, indicating a greater IP. The excreta concentrations of A1AT, I-FABP and SOD1 were unaltered by the experimental treatments. DEX increased (P<0.05) FN concentration in excreta compared with control birds. Conversely, inclusion of rye in the diet reduced (P<0.05) FN but increased (P<0.001) OVT in excreta. Independently, DEX decreased IAP (P<0.05) in excreta compared with control and rye-fed birds. The excreta concentration of LCN2 tended (P = 0.086) to increase in birds injected by DEX. There was no demonstrable effect of probiotic addition on any of the studied parameters. Among the tested biomarkers, FN, IAP, and LCN2 revealed promise as biomarkers of intestinal barrier function quantified by ELISA kits.

show abstract

Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis

Cited by 51 publications

References 39 publications

Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies

Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies

Gut Microbiome in Psoriasis: An Updated Review

Excreta biomarkers in response to different gut barrier dysfunction models and probiotic supplementation in broiler chickens

Contact Info

Product

Resources

About